Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --  -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

GlobeNewsWire • Aug 24, 2026

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.

The Motley Fool • Aug 23, 2026

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise

Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM's pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while strong gross margins offer operating leverage.

Seeking Alpha • Aug 18, 2026

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts

Rhythm Pharmaceuticals NASDAQ: RYTM is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat.

MarketBeat • Aug 17, 2026

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.

GlobeNewsWire • Aug 17, 2026

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.

Benzinga • Aug 12, 2026

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition

Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body weight in patients with a rare ​form of obesity caused by damage to the brain, ‌according to preliminary data from an ongoing mid-stage study.

Reuters • Aug 4, 2026

Rhythm Pharmaceuticals Q2 Earnings Call Highlights

Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO.

MarketBeat • Aug 4, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon --

GlobeNewsWire • Aug 4, 2026